<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-4.anc" start="17362" end="17369" sStart="-1" offset="0" sid="null" wn="6" wnkey="write%2:32:03::" annotator="tofox" text="RAM was involved in data extraction, quality scoring, analysis and &lt;b&gt;writing&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="3044" end="3049" sStart="null" offset="252" sid="r7.1.use.v.0685" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="QUORUM guidelines were followed [ 12 ] . Possible studies for inclusion were sought through searching the Cochrane Library (issue 4, 2001), Biological Abstracts (March 2002), MEDLINE (March 2002) and PubMed (March 2002) using rofecoxib as a free text term." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-4.anc" start="8391" end="8396" sStart="null" offset="0" sid="null" wn="1" wnkey="try%2:41:00::" annotator="veweser" text="Trials &lt;b&gt;tried&lt;/b&gt; to discourage remedication within 90 minutes, and two patients in one trial were excluded because they remedicated within 90 minutes, one on placebo and one on rofecoxib 50 mg [ 26 ] . This was not reported consistently ( Additional File 3)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-4.anc" start="8391" end="8396" sStart="null" offset="0" sid="null" wn="1" wnkey="try%2:41:00::" annotator="carichter" text="Trials &lt;b&gt;tried&lt;/b&gt; to discourage remedication within 90 minutes, and two patients in one trial were excluded because they remedicated within 90 minutes, one on placebo and one on rofecoxib 50 mg [ 26 ] . This was not reported consistently ( Additional File 3)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="10965" end="10971" sStart="null" offset="336" sid="r11.severe.j.0322" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="The five included studies were of generally high reporting quality (quality scores of 4 or 5), known to be associated with minimal reporting bias [ 30 31 ] . They all had a placebo control, used standardized pain intensity and relief scores in adult patients with established pain of moderate or severe intensity, and measured outcomes over at least six hours." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="3787" end="3793" sStart="null" offset="278" sid="r11.severe.j.0320" wn="1" wnkey="severe%5:00:00:intense:00" annotator="anfahmy" text="Criteria for inclusion for postoperative pain were: full journal publication, randomized controlled trials which included single dose treatment groups of oral rofecoxib and placebo, double blind design, baseline postoperative pain of moderate to severe intensity, patients over 15 years of age, at least 10 patients per group, and the pain outcome measures of total pain relief (TOTPAR) or summed pain intensity difference (SPID) over 4-6 hours or sufficient data to allow their calculation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="4310" end="4316" sStart="null" offset="245" sid="r11.severe.j.0321" wn="1" wnkey="severe%5:00:00:intense:00" annotator="adelpriore" text="Pain measures allowed for the calculation of TOTPAR or SPID were a standard five point pain relief scale (none, slight, moderate, good, complete), a standard four point pain intensity scale (none, mild, moderate, severe) or a standard visual analogue scale (VAS) for pain relief or pain intensity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="420" end="424" sStart="null" offset="377" sid="r7.poor.j.0861" wn="5" wnkey="poor%5:00:00:insufficient:00" annotator="veweser" text="Acute pain has been studied in single dose designs first proposed by Beecher and colleagues [ 1 2 ] and formalized by Houde and Wallenstein [ 3 ] . The problem with single trials is that while they can demonstrate statistical superiority of analgesic over placebo, variation because of random chance means that, if small, they provide a poor estimate of the size of the analgesic effect [ 4 ] . Combining results from clinically homogeneous trials in a meta-analysis gives an accurate estimate of the extent of the analgesic effect when sufficient numbers of patients have been randomized [ 4 5 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="420" end="424" sStart="null" offset="377" sid="r7.poor.j.0861" wn="4" wnkey="poor%3:00:02::" annotator="jeneale" text="Acute pain has been studied in single dose designs first proposed by Beecher and colleagues [ 1 2 ] and formalized by Houde and Wallenstein [ 3 ] . The problem with single trials is that while they can demonstrate statistical superiority of analgesic over placebo, variation because of random chance means that, if small, they provide a poor estimate of the size of the analgesic effect [ 4 ] . Combining results from clinically homogeneous trials in a meta-analysis gives an accurate estimate of the extent of the analgesic effect when sufficient numbers of patients have been randomized [ 4 5 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="5695" end="5701" sStart="null" offset="354" sid="r8.number.n.0597" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="For each trial, mean TOTPAR, SPID, VASTOTPAR or VASSPID values for each treatment group were converted to %maxTOTPAR by division into the calculated maximum value [ 15 ] . The proportion of patients in each treatment group who achieved at least 50%maxTOTPAR was calculated using valid equations [ 16 17 18 ] . The number of patients randomized was taken as the basis for calculations, to produce an intention to treat analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="10120" end="10127" sStart="null" offset="29" sid="r8.number.n.0960" wn="2" wnkey="number%1:23:00::" annotator="cgozo" text="For both there were negative numbers needed to harm (-11 and -12 respectively), showing that for every 11 or 12 patients given rofecoxib, one fewer was nauseous or vomited than with placebo." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="3561" end="3565" sStart="null" offset="52" sid="r9.full.j.0239" wn="2" wnkey="full%5:00:01:whole:00" annotator="cgozo" text="Criteria for inclusion for postoperative pain were: full journal publication, randomized controlled trials which included single dose treatment groups of oral rofecoxib and placebo, double blind design, baseline postoperative pain of moderate to severe intensity, patients over 15 years of age, at least 10 patients per group, and the pain outcome measures of total pain relief (TOTPAR) or summed pain intensity difference (SPID) over 4-6 hours or sufficient data to allow their calculation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="2060" end="2069" sStart="null" offset="37" sid="r8.1.different.j.0619" wn="1" wnkey="different%3:00:00::" annotator="brubin" text="For rofecoxib, this might be different." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-4.anc" start="376" end="382" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="veweser" text="Acute pain has been studied in single dose designs first proposed by Beecher and colleagues [ 1 2 ] and formalized by Houde and Wallenstein [ 3 ] . The problem with single trials is that while they can demonstrate statistical superiority of analgesic over placebo, variation because of random &lt;b&gt;chance&lt;/b&gt; means that, if small, they provide a poor estimate of the size of the analgesic effect [ 4 ] . Combining results from clinically homogeneous trials in a meta-analysis gives an accurate estimate of the extent of the analgesic effect when sufficient numbers of patients have been randomized [ 4 5 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-4.anc" start="376" end="382" sStart="null" offset="0" sid="null" wn="2" wnkey="chance%1:19:00::" annotator="carichter" text="Acute pain has been studied in single dose designs first proposed by Beecher and colleagues [ 1 2 ] and formalized by Houde and Wallenstein [ 3 ] . The problem with single trials is that while they can demonstrate statistical superiority of analgesic over placebo, variation because of random &lt;b&gt;chance&lt;/b&gt; means that, if small, they provide a poor estimate of the size of the analgesic effect [ 4 ] . Combining results from clinically homogeneous trials in a meta-analysis gives an accurate estimate of the extent of the analgesic effect when sufficient numbers of patients have been randomized [ 4 5 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="6860" end="6867" sStart="null" offset="9" sid="r11.benefit.n.0434" wn="2" wnkey="benefit%1:07:00::" annotator="anfahmy" text="Relative benefit or risk was considered to be statistically significant when the 95% confidence interval did not include 1. NNT or NNH values were only calculated when the relative risk or benefit was statistically significant, and are reported with the 95% confidence interval." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-4.anc" start="11280" end="11284" sStart="null" offset="242" sid="r11.able.j.0929" wn="1" wnkey="able%3:00:00::" annotator="anfahmy" text="The pain models, third molar dental extraction and orthopaedic surgery, are commonly used in research and choice of model does not appear to influence results in single-dose analgesic studies when patients are able to take oral medication [ 13 ] . Comparison of rofecoxib 50 mg with other analgesics over six hours is legitimate, because the same outcome was measured in the same way in the same patients over the same period of time, and with same comparator." />
  </sentences>
</list>